<DOC>
	<DOCNO>NCT00934544</DOCNO>
	<brief_summary>This open label , randomize study compare efficacy safety randomize 2:1 INC424/INCB018424 tablet versus best-available therapy , select investigator . The purpose compare efficacy , safety tolerability INC424/INCB018424 give twice daily best-available therapy , subject primary myelofibrosis ( PMF ) , post polycythemia vera myelofibrosis ( PPV-MF ) post essential thrombocythemia myelofibrosis ( PET-MF ) .</brief_summary>
	<brief_title>Controlled Myelofibrosis Study With Oral Janus-associated Kinase ( JAK ) Inhibitor Treatment-II : The COMFORT-II Trial</brief_title>
	<detailed_description>Male female individual , age 18 year old diagnose Myelofibrosis ( either Primary Myelofibrosis ( PMF ) Post-Polycythemia Vera Myelofibrosis ( PPV-MF ) Post-Essential Thrombocythemia Myelofibrosis ( PET-MF ) , observe palpable splenomegaly , candidate stem cell transplantation , 2 risk factor , thereby place intermediate-2 high-risk prognostic group may enroll . Subjects permit received prior therapy MF . This open label , randomize study compare efficacy safety INCB018424 tablets versus best-available therapy , select investigator . The purpose compare efficacy , safety tolerability INCB018424 give twice daily best-available therapy , subject primary myelofibrosis ( PMF ) , post polycythemia vera myelofibrosis ( PPV-MF ) post essential thrombocythemia myelofibrosis ( PET-MF ) .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>Subjects must diagnose PMF , PPVMF PETMF accord 2008 World Health Organization criterion Subjects MF require therapy must classify high risk OR intermediate risk level 2 accord prognostic factor define International Working Group Subjects ECOG performance status 0 , 1 , 2 3 Subjects peripheral blood blast count &lt; 10 % . Subjects previously receive treatment JAK inhibitor Subjects life expectancy le 6 month Subjects inadequate bone marrow reserve demonstrate specific clinical laboratory count Subjects history platelet count &lt; 50,000/µL ANC &lt; 500/µL except treatment myeloproliferative disorder treatment cytotoxic therapy reason Subjects inadequate liver renal function Subjects clinically significant bacterial , fungal , parasitic viral infection require therapy Subjects active malignancy previous 5 year except specific skin cancer Subjects severe cardiac condition Subjects splenic irradiation within 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Myelofibrosis</keyword>
	<keyword>Post-Polycythemia Vera Myelofibrosis</keyword>
	<keyword>Post-Essential Thrombocythemia Myelofibrosis</keyword>
</DOC>